Immunoconjugates

DBCAT000152Pharmacologic class

Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. A DrugBank category of 15 drugs. 11 of them are approved.

Also known as: Immunoconjugate · Radioimmunoconjugate · Radioimmunoconjugates
Drugs: Abatacept
Belatacept
Bivatuzumab mertansine
Brentuximab vedotin
Cantuzumab mertansine
Datopotamab deruxtecan
Disitamab vedotin
Gemtuzumab ozogamicin
Inotuzumab ozogamicin
Lorvotuzumab mertansine
Mirvetuximab soravtansine
Moxetumomab pasudotox
Telisotuzumab vedotin
Tisotumab vedotin
Trastuzumab emtansine

What you can answer from here — as of August 24, 2016

15DrugsEach linked to its full drug card

Listed above

18Drug targetsEvery drug–target pair in the class, with bond type

100Marketed productsAcross the regions we cover, with dosage forms and routes

5Routes of administrationHow the drugs in this class are given

Which targets do Immunoconjugates share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account